レーバー先天性黒内障の世界市場レポート 2025年

レーバー先天性黒内障市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.9％で、13億4,000万米ドルに成長します。予測期間の成長は、遺伝子治療への投資の増加、遺伝性網膜疾患の有病率の上昇、新しい治療法に対する規制当局の承認、臨床試験の拡大、ヘルスケア支出の増加が原動力になると予想されます。予測期間の主な動向としては、CRISPRベースの治療法の台頭、バイオテクノロジー企業間の連携強化、個別化医療の開発、遠隔眼科の成長、網膜画像技術の進歩などが挙げられます。

遺伝性網膜疾患の有病率の上昇は、レーバー先天性黒内障（LCA）市場の成長を促進すると予想されます。遺伝性網膜疾患（IRD）は、視力を司る目の奥の光感受性組織である網膜に影響を及ぼす遺伝性疾患です。これらの疾患の増加は、遺伝子検査の進歩、認知度の向上、診断の向上、寿命の延長に起因しています。遺伝子検査の進歩によりIRDの診断が容易になり、より多くの症例が特定されるようになりました。レーバー先天性黒内障は、遺伝子の変異や疾患のメカニズムを明らかにすることで、遺伝性網膜疾患の理解を深め、標的療法や治療の開発に貢献しています。例えば、2025年1月の英国議会下院図書館によると、2024年には英国で約2万5,000人が遺伝性網膜疾患に罹患し、年間2％の増加を示しています。その結果、遺伝性網膜疾患の有病率の増加がレーバー先天性黒内障市場の成長を牽引しています。

レーバー先天性黒内障市場の各社は、視力回復と疾患管理を改善するため、RNAベースの治療開発にますます力を入れています。RNAベースの治療法は、RNA分子を利用して遺伝的プロセスを標的とし、病気を治療します。これらの治療法には、mRNAワクチン、siRNA治療法、アンチセンスオリゴヌクレオチド、RNAアプタマーなどが含まれます。例えば、2025年1月、フランスの製薬会社であるLaboratoires Thea S.A.S.は、遺伝性網膜疾患のRNA療法を推進する事業部門であるSepul Bioを立ち上げました。セピュール・バイオ社は、特にレーバー先天性黒内障10（LCA10）に対するsepofarsenとUSH2A関連網膜色素変性症に対するultevursenをターゲットとしています。ultevursenのLUNAフェーズ2b臨床試験で最初の患者への投与に成功したことを受け、セパルバイオ社はこれらの稀な遺伝性疾患への対応で大きく前進する態勢を整えています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のレーバー先天性黒内障PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のレーバー先天性黒内障市場：成長率分析
• 世界のレーバー先天性黒内障市場の実績：規模と成長、2019年～2024年
• 世界のレーバー先天性黒内障市場の予測：規模と成長、2024年～2029年、2034年
• 世界のレーバー先天性黒内障総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のレーバー先天性黒内障市場：治療タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 遺伝子治療
• 医薬品
• 人工網膜
• 補助器具
• その他の治療法
• 世界のレーバー先天性黒内障市場：発症年齢別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 先天性レーバー先天性黒内障（LCA）（出生時から）
• 幼児期のレーバー先天性黒内障（LCA）（1～5歳）
• 遅発性レーバー先天性黒内障（LCA）（6歳以上）
• 世界のレーバー先天性黒内障市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 直接入札
• 小売売上高
• 世界のレーバー先天性黒内障市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 専門眼科クリニック
• 眼科研究センター
• 在宅ケア設定
• その他のエンドユーザー
• 世界のレーバー先天性黒内障市場、遺伝子治療の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• RPE65遺伝子置換療法
• CRISPRベースの遺伝子編集
• AAV（アデノ随伴ウイルス）ベクター療法
• 新たな実験的遺伝子治療
• 世界のレーバー先天性黒内障市場、医薬品の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• レチノイドベースの治療法
• 神経保護剤
• 抗炎症薬
• 抗酸化療法
• 世界のレーバー先天性黒内障市場、人工網膜のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 埋め込み型網膜チップ
• 人工網膜刺激装置
• バイオニックアイテクノロジー
• 世界のレーバー先天性黒内障市場、補助器具の種類別細分化、実績と予測、2019年～2024年、2024年～2029年、2034年
• 低視力補助具
• スクリーンリーダーと点字デバイス
• 視覚障害者のための移動補助具
• 世界のレーバー先天性黒内障市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 幹細胞療法
• 光遺伝学に基づく治療
• 視覚リハビリテーションプログラム
• 栄養と食事介入

第7章 地域別・国別分析

• 世界のレーバー先天性黒内障市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のレーバー先天性黒内障市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• レーバー先天性黒内障市場：競合情勢
• レーバー先天性黒内障市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Invitae Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Novelion Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Andelyn Biosciences Inc.
• CD Genomics Inc.
• Editas Medicine Inc.
• MeiraGTx Holdings plc
• Sangamo Therapeutics Inc.
• LKC Technologies Inc.
• Aldeyra Therapeutics Inc.
• Asper Biogene OU
• Allergan Inc.
• ProQR Therapeutics N.V.
• GenSight Biologics S.A.
• Ocugen Inc.
• IVERIC bio Inc.（formerly Ophthotech Corporation）
• Atsena Therapeutics Inc.
• HuidaGene Therapeutics Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• レーバー先天性黒内障市場2029年：新たな機会を提供する国
• レーバー先天性黒内障市場2029年：新たな機会を提供するセグメント
• レーバー先天性黒内障市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Leber congenital amaurosis (LCA) is an inherited eye disorder that leads to significant vision impairment or blindness from a young age, caused by genetic mutations that hinder the retina's ability to process light. The condition is marked by weak visual responses, involuntary eye movements (nystagmus), and severe farsightedness due to malfunctioning photoreceptors and gradual retinal degeneration.

Treatment options for LCA primarily include gene therapy, medication, retinal prosthetics, assistive technologies, and other interventions. Gene therapy is a technique that uses genetic material to treat or prevent disorders such as LCA by fixing defective genes. LCA is classified based on the age of onset, including congenital LCA (present at birth), early childhood LCA (1-5 years old), and late-onset LCA (after 6 years). Medications for LCA are distributed through various means such as direct tenders and retail sales, and are used in hospitals, specialized eye clinics, ophthalmology research centers, and home care environments.

The leber congenital amaurosis market research report is one of a series of new reports from The Business Research Company that provides leber congenital amaurosis market statistics, including the leber congenital amaurosis industry global market size, regional shares, competitors with the leber congenital amaurosis market share, detailed leber congenital amaurosis market segments, market trends, and opportunities, and any further data you may need to thrive in the leber congenital amaurosis industry. This leber congenital amaurosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The leber congenital amaurosis market size has grown strongly in recent years. It will grow from $1.01 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth observed during the historical period can be attributed to factors such as increased awareness of rare eye diseases, greater government funding, enhanced diagnostic methods, the expansion of ophthalmic research centers, and patient advocacy efforts.

The leber congenital amaurosis market size is expected to see strong growth in the next few years. It will grow to $1.34 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period is expected to be driven by higher investments in gene therapy, the rising prevalence of inherited retinal disorders, regulatory approvals for new treatments, the expansion of clinical trials, and an increase in healthcare spending. Key trends for the forecast period include the rise of CRISPR-based therapies, greater collaboration between biotechnology companies, the development of personalized medicine, the growth of teleophthalmology, and advancements in retinal imaging technologies.

The rising prevalence of inherited retinal diseases is expected to drive the growth of the leber congenital amaurosis (LCA) market. Inherited retinal diseases (IRDs) are genetic disorders that affect the retina, the light-sensitive tissue at the back of the eye responsible for vision. The increase in these diseases can be attributed to advancements in genetic testing, greater awareness, better diagnosis, and longer life expectancy. Progress in genetic testing has made it easier to diagnose IRDs, resulting in more cases being identified. Leber congenital amaurosis has helped enhance the understanding of inherited retinal diseases by revealing genetic mutations and disease mechanisms, contributing to the development of targeted therapies and treatments. For example, according to the UK Parliament's House of Commons Library in January 2025, approximately 25,000 people in the UK were affected by inherited retinal diseases in 2024, marking a 2% annual increase. As a result, the growing prevalence of inherited retinal diseases is driving the growth of the leber congenital amaurosis market.

Companies in the leber congenital amaurosis market are increasingly focusing on developing RNA-based treatments to improve vision restoration and disease management. RNA-based therapies utilize RNA molecules to target genetic processes and treat diseases. These therapies include mRNA vaccines, siRNA therapies, antisense oligonucleotides, and RNA aptamers. For instance, in January 2025, Laboratoires Thea S.A.S., a French pharmaceutical company, launched Sepul Bio, a business unit dedicated to advancing RNA therapies for inherited retinal diseases. Sepul Bio is specifically targeting sepofarsen for leber congenital amaurosis 10 (LCA10) and ultevursen for USH2A-associated retinitis pigmentosa. Following the successful dosing of the first patient in the LUNA Phase 2b clinical trial for ultevursen, Sepul Bio is poised to make significant progress in addressing these rare genetic disorders.

In October 2024, Ocuphire Pharma Inc., a US-based biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. This acquisition aims to create a leading clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs). Opus Genetics Inc. is a US-based company that specializes in developing gene therapies for IRDs.

Major players in the leber congenital amaurosis market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Invitae Corporation, Novelion Therapeutics Inc., Andelyn Biosciences Inc., CD Genomics Inc., Editas Medicine Inc., MeiraGTx Holdings plc, Sangamo Therapeutics Inc., LKC Technologies Inc., Aldeyra Therapeutics Inc., Asper Biogene OU, Allergan Inc., ProQR Therapeutics N.V., GenSight Biologics S.A., Ocugen Inc., IVERIC bio Inc. (formerly Ophthotech Corporation), Atsena Therapeutics Inc., HuidaGene Therapeutics Co. Ltd.

North America was the largest region in the leber congenital amaurosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leber congenital amaurosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leber congenital amaurosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leber congenital amaurosis (LCA) market consists of revenues earned by entities by providing services such as clinical trial services, healthcare and patient support services, vision rehabilitation services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The leber congenital amaurosis (LCA) market also includes sales of retinal implants, diagnostic testing kits, assistive devices, and gene therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leber Congenital Amaurosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leber congenital amaurosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leber congenital amaurosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leber congenital amaurosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Gene Therapy; Pharmaceutical Drugs; Retinal Prosthesis; Assistive Devices; Other Treatments
• 2) By Age Of Onset: Congenital Leber Congenital Amaurosis (LCA) (From Birth); Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years); Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
• 3) By Distribution Channel:; Direct Tender; Retail Sales
• 4) By End User: Hospitals; Specialized Eye Clinics; Ophthalmology Research Centers; Home Care Settings; Other End Users
• Subsegments:
• 1) By Gene Therapy: RPE65 Gene Replacement Therapy; CRISPR-Based Gene Editing; AAV (Adeno-Associated Virus) Vector Therapy; Emerging Experimental Gene Therapies
• 2) By Pharmaceutical Drugs: Retinoid-Based Therapies; Neuroprotective Agents; Anti-Inflammatory Drugs; Antioxidant Therapies
• 3) By Retinal Prosthesis: Implantable Retinal Chips; Artificial Retinal Stimulation Devices; Bionic Eye Technology
• 4) By Assistive Devices: Low Vision Aids; Screen Readers and Braille Devices; Mobility Aids for Vision Impairment
• 5) By Other Treatments: Stem Cell Therapy; Optogenetics-Based Treatments; Visual Rehabilitation Programs; Nutritional and Dietary Interventions
• Companies Mentioned: Sanofi S.A.; Novartis AG; Astellas Pharma Inc.; Invitae Corporation; Novelion Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Leber Congenital Amaurosis Market Characteristics

3. Leber Congenital Amaurosis Market Trends And Strategies

4. Leber Congenital Amaurosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Leber Congenital Amaurosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Leber Congenital Amaurosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Leber Congenital Amaurosis Market Growth Rate Analysis
• 5.4. Global Leber Congenital Amaurosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Leber Congenital Amaurosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Leber Congenital Amaurosis Total Addressable Market (TAM)

6. Leber Congenital Amaurosis Market Segmentation

• 6.1. Global Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapy
• Pharmaceutical Drugs
• Retinal Prosthesis
• Assistive Devices
• Other Treatments
• 6.2. Global Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congenital Leber Congenital Amaurosis (LCA) (From Birth)
• Early Childhood Leber Congenital Amaurosis (LCA) (1-5 Years)
• Late-Onset Leber Congenital Amaurosis (LCA) (6 Years And Above)
• 6.3. Global Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Tender
• Retail Sales
• 6.4. Global Leber Congenital Amaurosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialized Eye Clinics
• Ophthalmology Research Centers
• Home Care Settings
• Other End Users
• 6.5. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RPE65 Gene Replacement Therapy
• CRISPR-Based Gene Editing
• AAV (Adeno-Associated Virus) Vector Therapy
• Emerging Experimental Gene Therapies
• 6.6. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Pharmaceutical Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retinoid-Based Therapies
• Neuroprotective Agents
• Anti-Inflammatory Drugs
• Antioxidant Therapies
• 6.7. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Retinal Prosthesis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Implantable Retinal Chips
• Artificial Retinal Stimulation Devices
• Bionic Eye Technology
• 6.8. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Assistive Devices, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low Vision Aids
• Screen Readers and Braille Devices
• Mobility Aids for Vision Impairment
• 6.9. Global Leber Congenital Amaurosis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stem Cell Therapy
• Optogenetics-Based Treatments
• Visual Rehabilitation Programs
• Nutritional and Dietary Interventions

7. Leber Congenital Amaurosis Market Regional And Country Analysis

• 7.1. Global Leber Congenital Amaurosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Leber Congenital Amaurosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Leber Congenital Amaurosis Market

• 8.1. Asia-Pacific Leber Congenital Amaurosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Leber Congenital Amaurosis Market

• 9.1. China Leber Congenital Amaurosis Market Overview
• 9.2. China Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Leber Congenital Amaurosis Market

• 10.1. India Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Leber Congenital Amaurosis Market

• 11.1. Japan Leber Congenital Amaurosis Market Overview
• 11.2. Japan Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Leber Congenital Amaurosis Market

• 12.1. Australia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Leber Congenital Amaurosis Market

• 13.1. Indonesia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Leber Congenital Amaurosis Market

• 14.1. South Korea Leber Congenital Amaurosis Market Overview
• 14.2. South Korea Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Leber Congenital Amaurosis Market

• 15.1. Western Europe Leber Congenital Amaurosis Market Overview
• 15.2. Western Europe Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Leber Congenital Amaurosis Market

• 16.1. UK Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Leber Congenital Amaurosis Market

• 17.1. Germany Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Leber Congenital Amaurosis Market

• 18.1. France Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Leber Congenital Amaurosis Market

• 19.1. Italy Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Leber Congenital Amaurosis Market

• 20.1. Spain Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Leber Congenital Amaurosis Market

• 21.1. Eastern Europe Leber Congenital Amaurosis Market Overview
• 21.2. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Leber Congenital Amaurosis Market

• 22.1. Russia Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Leber Congenital Amaurosis Market

• 23.1. North America Leber Congenital Amaurosis Market Overview
• 23.2. North America Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Leber Congenital Amaurosis Market

• 24.1. USA Leber Congenital Amaurosis Market Overview
• 24.2. USA Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Leber Congenital Amaurosis Market

• 25.1. Canada Leber Congenital Amaurosis Market Overview
• 25.2. Canada Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Leber Congenital Amaurosis Market

• 26.1. South America Leber Congenital Amaurosis Market Overview
• 26.2. South America Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Leber Congenital Amaurosis Market

• 27.1. Brazil Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Leber Congenital Amaurosis Market

• 28.1. Middle East Leber Congenital Amaurosis Market Overview
• 28.2. Middle East Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Leber Congenital Amaurosis Market

• 29.1. Africa Leber Congenital Amaurosis Market Overview
• 29.2. Africa Leber Congenital Amaurosis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Leber Congenital Amaurosis Market, Segmentation By Age Of Onset, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Leber Congenital Amaurosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Leber Congenital Amaurosis Market Competitive Landscape And Company Profiles

• 30.1. Leber Congenital Amaurosis Market Competitive Landscape
• 30.2. Leber Congenital Amaurosis Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Invitae Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novelion Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Leber Congenital Amaurosis Market Other Major And Innovative Companies

• 31.1. Andelyn Biosciences Inc.
• 31.2. CD Genomics Inc.
• 31.3. Editas Medicine Inc.
• 31.4. MeiraGTx Holdings plc
• 31.5. Sangamo Therapeutics Inc.
• 31.6. LKC Technologies Inc.
• 31.7. Aldeyra Therapeutics Inc.
• 31.8. Asper Biogene OU
• 31.9. Allergan Inc.
• 31.10. ProQR Therapeutics N.V.
• 31.11. GenSight Biologics S.A.
• 31.12. Ocugen Inc.
• 31.13. IVERIC bio Inc. (formerly Ophthotech Corporation)
• 31.14. Atsena Therapeutics Inc.
• 31.15. HuidaGene Therapeutics Co. Ltd.

32. Global Leber Congenital Amaurosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leber Congenital Amaurosis Market

34. Recent Developments In The Leber Congenital Amaurosis Market

35. Leber Congenital Amaurosis Market High Potential Countries, Segments and Strategies

• 35.1 Leber Congenital Amaurosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Leber Congenital Amaurosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Leber Congenital Amaurosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer